Nabriva hit with another FDA setback with complete response letter for antibiotic Contepo

Nabriva Therapeutics threaded the needle from biotech to pharma after it notched its first FDA approval for antibiotic Xenleta back in August. But manufacturing issues for a second antibiotic in Nabriva's pipeline have drawn the FDA's ire, and now the pandemic has stopped the drugmaker's second shot at an approval.